Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
Open Access
- 2 March 2004
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 90 (6) , 1156-1162
- https://doi.org/10.1038/sj.bjc.6601709
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal CancerJournal of Clinical Oncology, 2003
- Interleukin‐2, interferon‐α, 5‐fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinomaCancer, 2002
- Thirteen‐year, long‐term efficacy of interferon 2α and interleukin 2‐based home therapy in patients with advanced renal cell carcinomaCancer, 2002
- The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2European Journal Of Cancer, 1994
- A Comparison of 2 Modes of Administration of Recombinant Interleukin-2: Continuous Intravenous Infusion Alone Versus Subcutaneous Administration plus Interferon Alpha in Patients with Advanced Renal Cell Carcinoma.Cancer Biotherapy, 1993
- The Impact of Interleukin-2 on Survival in Renal Cancer: A Multivariate AnalysisCancer Biotherapy, 1993
- Phase I study comparing continuous infusion of recombinant interleukin-2 by subcutaneous or intravenous administrationEuropean Journal Of Cancer, 1992
- Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II studyEuropean Journal of Cancer and Clinical Oncology, 1991
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985